Research programme: apolipoprotein E-mimetic peptide therapeutics - Cognosci Inc.

Drug Profile

Research programme: apolipoprotein E-mimetic peptide therapeutics - Cognosci Inc.

Alternative Names: COG 112; COG 133; COG 1410; COG 241; COG 68

Latest Information Update: 17 Mar 2011

Price : $50

At a glance

  • Originator Duke University
  • Developer Cognosci
  • Class Peptides; Small molecules
  • Mechanism of Action Apolipoprotein E agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Alzheimer's disease; Brain injuries; Multiple sclerosis; Subarachnoid haemorrhage

Highest Development Phases

  • Preclinical Alzheimer's disease; Brain injuries; Multiple sclerosis; Subarachnoid haemorrhage
  • No development reported Chronic lymphocytic leukaemia; Parkinson's disease; Rheumatoid arthritis
  • Discontinued Inflammatory bowel diseases

Most Recent Events

  • 28 Feb 2011 No development reported - Preclinical for Chronic lymphocytic leukaemia in USA (unspecified route)
  • 28 Feb 2011 Preclinical trials in Alzheimer's disease in USA (unspecified route)
  • 28 Feb 2011 No development reported for Parkinson's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top